Ireland regulator reports manufacturing deficiency at Biocon’s Bengaluru plant
PTI, May 4, 2022, 10:09 AM IST
Image: Official website
Biotechnology major Biocon Biologics on Tuesday said Ireland’s health regulator has reported some deficiencies in the manufacturing process at the company’s plant in Bengaluru.
The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics’ new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.
“The inspection report contains no ‘critical’ observations and only one of the deficiencies is categorised as ‘major’ which is being addressed expeditiously in consultation with the regulatory agency,” the spokesperson added.
The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.
Biocon Biologics is a subsidiary of Biocon Ltd.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
CBDT allows tax officials to waive or reduce interest due from assessee
Markets fall in early trade amid unabated foreign fund outflows
New software for fast-tracking project approvals: Karnataka Minister Patil
In-flight passengers can access WiFi services only when allowed, say new rules
SEBI mulls separation of non-regulated activities; ‘cross-default’ definition for debenture trustees
MUST WATCH
Latest Additions
Clash between 2 groups leads to stone pelting at temple in Delhi’s Jahangirpuri
CBI forms SIT to probe into Tirupati laddu adulteration allegations
Bengaluru airport collaborates with Echoes of Earth festival for 5th consecutive year
Ex-PM Gowda jumps into campaign fray, seeks support for grandson in Channapatna bypoll
Will appear before Lokayukta for questioning in MUDA case, says CM Siddaramaiah
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.